116 related articles for article (PubMed ID: 15731318)
21. [Significance of timing ovulation induction using HCG or synthetic LH-RH in therapy of sterility].
Gigon U; Stamm O; Werder H
Geburtshilfe Frauenheilkd; 1973 Jul; 33(7):567-75. PubMed ID: 4581932
[No Abstract] [Full Text] [Related]
22. Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome.
Eckmann KR; Kockler DR
Ann Pharmacother; 2009 Jul; 43(7):1338-46. PubMed ID: 19584394
[TBL] [Abstract][Full Text] [Related]
23. [Aromatase inhibitors--is it a new opportunity in the treatment of infertility?].
Vladimirov IaK
Akush Ginekol (Sofiia); 2004; 43(2):50-5. PubMed ID: 15185531
[TBL] [Abstract][Full Text] [Related]
24. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.
De Placido G; Mollo A; Clarizia R; Strina I; Conforti S; Alviggi C
Fertil Steril; 2006 Jan; 85(1):247-50. PubMed ID: 16412769
[TBL] [Abstract][Full Text] [Related]
25. Role of LH in controlled ovarian stimulation.
Wiesak T
Reprod Biol; 2002 Nov; 2(3):215-27. PubMed ID: 14666146
[TBL] [Abstract][Full Text] [Related]
26. Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle-stimulating hormone ratio.
Elnashar A; Fouad H; Eldosoky M; Saeid N
Fertil Steril; 2006 Feb; 85(2):511-3. PubMed ID: 16595244
[TBL] [Abstract][Full Text] [Related]
27. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
28. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin.
Grøndahl ML; Borup R; Lee YB; Myrhøj V; Meinertz H; Sørensen S
Fertil Steril; 2009 May; 91(5):1820-30. PubMed ID: 18439596
[TBL] [Abstract][Full Text] [Related]
29. New advances in ovulation induction.
Kafy S; Tulandi T
Curr Opin Obstet Gynecol; 2007 Jun; 19(3):248-52. PubMed ID: 17495641
[TBL] [Abstract][Full Text] [Related]
30. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today?
Altmäe S; Hovatta O; Stavreus-Evers A; Salumets A
Hum Reprod Update; 2011; 17(6):813-28. PubMed ID: 21862569
[TBL] [Abstract][Full Text] [Related]
31. Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists?
Orvieto R; Rabinson J; Meltcer S; Gemer O; Anteby EY; Zohav E
Fertil Steril; 2008 Mar; 89(3):736-7. PubMed ID: 17498708
[TBL] [Abstract][Full Text] [Related]
32. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of aromatase inhibitor co-treatment for controlled ovarian stimulation.
Bedaiwy MA; Forman R; Mousa NA; Al Inany HG; Casper RF
Hum Reprod; 2006 Nov; 21(11):2838-44. PubMed ID: 16877370
[TBL] [Abstract][Full Text] [Related]
34. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
35. Patient-tailored conventional ovulation induction algorithms in anovulatory infertility.
van Santbrink EJ; Eijkemans MJ; Laven JS; Fauser BC
Trends Endocrinol Metab; 2005 Oct; 16(8):381-9. PubMed ID: 16129615
[TBL] [Abstract][Full Text] [Related]
36. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction.
Andersen CY; Humaidan P; Ejdrup HB; Bungum L; Grøndahl ML; Westergaard LG
Hum Reprod; 2006 Aug; 21(8):2126-30. PubMed ID: 16682403
[TBL] [Abstract][Full Text] [Related]
37. Homologous intrauterine insemination in controlled ovarian hyperstimulation cycles: a comparison among three different regimens.
Casadei L; Zamaro V; Calcagni M; Ticconi C; Dorrucci M; Piccione E
Eur J Obstet Gynecol Reprod Biol; 2006 Dec; 129(2):155-61. PubMed ID: 16687201
[TBL] [Abstract][Full Text] [Related]
38. A randomized comparison of ovulation induction and hormone profile between the aromatase inhibitor anastrozole and clomiphene citrate in women with infertility.
Wu HH; Wang NM; Cheng ML; Hsieh JN
Gynecol Endocrinol; 2007 Feb; 23(2):76-81. PubMed ID: 17454156
[TBL] [Abstract][Full Text] [Related]
39. The use of aromatase inhibitors in in vitro fertilization.
Garcia-Velasco JA
Fertil Steril; 2012 Dec; 98(6):1356-8. PubMed ID: 23062732
[TBL] [Abstract][Full Text] [Related]
40. The influence of urinary versus recombinant gonadotropin on serum P-selectin levels in vivo.
Orvieto R; La Marca A; Badir W; Golan O; Bar J; Fisch B
Gynecol Endocrinol; 2005 Apr; 20(4):185-7. PubMed ID: 16019359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
